KRW 4745.0
(-1.35%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | 79.38 Billion KRW | 8428.99% |
2022 | 930.78 Million KRW | -40.27% |
2021 | 1.55 Billion KRW | -92.77% |
2020 | 21.54 Billion KRW | 936.93% |
2019 | 2.07 Billion KRW | 0.0% |
2018 | - KRW | 0.0% |
2017 | - KRW | 0.0% |
2016 | - KRW | 0.0% |
2015 | - KRW | 0.0% |
2014 | - KRW | 0.0% |
2013 | - KRW | -100.0% |
2012 | 20 Billion KRW | -50.0% |
2011 | 40 Billion KRW | 100.0% |
2010 | 20 Billion KRW | -33.33% |
2009 | 30 Billion KRW | 0.0% |
2008 | 30 Billion KRW | 0.0% |
2007 | - KRW | 0.0% |
2006 | - KRW | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q2 | 79.67 Billion KRW | 0.13% |
2024 Q1 | 79.56 Billion KRW | 0.22% |
2023 Q2 | 902.69 Million KRW | -8.68% |
2023 FY | 79.38 Billion KRW | 8428.99% |
2023 Q4 | 79.38 Billion KRW | 157.75% |
2023 Q1 | 988.52 Million KRW | 6.2% |
2023 Q3 | 30.8 Billion KRW | 3312.04% |
2022 Q3 | 11.15 Billion KRW | 788.23% |
2022 Q2 | 1.25 Billion KRW | -14.36% |
2022 Q1 | 1.46 Billion KRW | -5.86% |
2022 FY | 930.78 Million KRW | -40.27% |
2022 Q4 | 930.78 Million KRW | -91.66% |
2021 Q2 | 21.75 Billion KRW | 0.99% |
2021 FY | 1.55 Billion KRW | -92.77% |
2021 Q3 | 1.65 Billion KRW | -92.38% |
2021 Q4 | 1.55 Billion KRW | -5.95% |
2021 Q1 | 21.53 Billion KRW | -0.05% |
2020 FY | 21.54 Billion KRW | 936.93% |
2020 Q2 | 76.88 Billion KRW | -0.13% |
2020 Q3 | 21.82 Billion KRW | -71.62% |
2020 Q4 | 21.54 Billion KRW | -1.25% |
2020 Q1 | 76.98 Billion KRW | 3604.65% |
2019 Q1 | 27.63 Million KRW | 0.0% |
2019 Q4 | 2.07 Billion KRW | 5829.71% |
2019 FY | 2.07 Billion KRW | 0.0% |
2019 Q2 | 13.01 Billion KRW | 47016.97% |
2019 Q3 | 35.04 Million KRW | -99.73% |
2018 Q1 | - KRW | 0.0% |
2018 FY | - KRW | 0.0% |
2018 Q4 | - KRW | 0.0% |
2018 Q3 | - KRW | 0.0% |
2018 Q2 | - KRW | 0.0% |
2017 Q2 | - KRW | 0.0% |
2017 Q1 | - KRW | 0.0% |
2017 Q4 | - KRW | 0.0% |
2017 FY | - KRW | 0.0% |
2017 Q3 | - KRW | 0.0% |
2016 Q4 | - KRW | 0.0% |
2016 FY | - KRW | 0.0% |
2016 Q1 | - KRW | 0.0% |
2016 Q2 | - KRW | 0.0% |
2016 Q3 | - KRW | 0.0% |
2015 Q1 | - KRW | 0.0% |
2015 FY | - KRW | 0.0% |
2015 Q4 | - KRW | 0.0% |
2015 Q3 | - KRW | 0.0% |
2015 Q2 | - KRW | 0.0% |
2014 Q4 | - KRW | 0.0% |
2014 FY | - KRW | 0.0% |
2014 Q2 | - KRW | 0.0% |
2014 Q3 | - KRW | 0.0% |
2013 Q4 | - KRW | 0.0% |
2013 FY | - KRW | -100.0% |
2013 Q1 | 20 Billion KRW | 0.0% |
2012 Q4 | 20 Billion KRW | -50.0% |
2012 Q1 | 40 Billion KRW | 0.0% |
2012 FY | 20 Billion KRW | -50.0% |
2012 Q2 | 40 Billion KRW | 0.0% |
2012 Q3 | 40 Billion KRW | 0.0% |
2011 FY | 40 Billion KRW | 100.0% |
2011 Q3 | 20 Billion KRW | 0.0% |
2011 Q1 | 20 Billion KRW | -33.33% |
2011 Q2 | 20 Billion KRW | 0.0% |
2010 Q3 | 30 Billion KRW | 0.0% |
2010 Q4 | 30 Billion KRW | 0.0% |
2010 Q2 | 30 Billion KRW | 0.0% |
2010 Q1 | 30 Billion KRW | 0.0% |
2010 FY | 20 Billion KRW | -33.33% |
2009 Q4 | 30 Billion KRW | 0.0% |
2009 Q3 | 30 Billion KRW | 0.0% |
2009 Q2 | 30 Billion KRW | 0.0% |
2009 FY | 30 Billion KRW | 0.0% |
2008 Q4 | 30 Billion KRW | 0.0% |
2008 Q2 | - KRW | 0.0% |
2008 Q3 | 30 Billion KRW | 0.0% |
2008 FY | 30 Billion KRW | 0.0% |
2007 FY | - KRW | 0.0% |
2007 Q2 | - KRW | 0.0% |
2007 Q3 | - KRW | 0.0% |
2007 Q4 | - KRW | 0.0% |
2006 FY | - KRW | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
Dongwha Pharm.Co.,Ltd | 48.25 Billion KRW | -64.514% |
Yuhan Corporation | 230.07 Billion KRW | 65.495% |
Yuhan Corporation | 230.07 Billion KRW | 65.495% |
Yuyu Pharma, Inc. | 39.4 Billion KRW | -101.453% |
Yuyu Pharma, Inc. | 39.4 Billion KRW | -101.453% |
Yuyu Pharma, Inc. | 39.4 Billion KRW | -101.453% |
Ildong Holdings Co., Ltd. | 382.06 Billion KRW | 79.221% |
Samil Pharmaceutical Co.,Ltd | 175.87 Billion KRW | 54.863% |
Dong-A Socio Holdings Co., Ltd. | 691.88 Billion KRW | 88.526% |
JW Pharmaceutical Corporation | 170.28 Billion KRW | 53.379% |
JW Pharmaceutical Corporation | 170.28 Billion KRW | 53.379% |
JW Pharmaceutical Corporation | 170.28 Billion KRW | 53.379% |
SAMSUNG PHARM. Co., LTD. | 595.48 Million KRW | -13231.453% |
Chong Kun Dang Holdings Corp. | 468.03 Billion KRW | 83.038% |
Dong Sung Bio Pharm.Co.,Ltd. | 43.27 Billion KRW | -83.457% |
HANDOK Inc. | 300.01 Billion KRW | 73.539% |
Jeil Pharma Holdings Inc | 173.03 Billion KRW | 54.12% |
Kukje Pharma Co., Ltd. | 30.66 Billion KRW | -158.909% |
Aprogen pharmaceuticals,Inc. | 180.99 Billion KRW | 56.139% |
Ilsung Pharmaceuticals Co., Ltd. | 238.12 Million KRW | -33238.192% |
Daewon Pharmaceutical Co., Ltd. | 146.04 Billion KRW | 45.644% |
Yungjin Pharm. Co., Ltd. | 66.88 Billion KRW | -18.697% |
Boryung Corporation | 204.21 Billion KRW | 61.126% |
Hyundai Pharmaceutical Co., Ltd. | 39.2 Billion KRW | -102.492% |
Samjin Pharmaceuticals Co., Ltd. | 118.63 Billion KRW | 33.085% |
Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | 6.779% |
Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | 6.779% |
Suheung Co., Ltd. | 467.85 Billion KRW | 83.032% |
Kwang Dong Pharmaceutical Co., Ltd. | 235.64 Billion KRW | 66.31% |
Hanall Biopharma Co.,Ltd | 1.29 Billion KRW | -6051.498% |
Whan In Pharm Co.,Ltd. | 632.02 Million KRW | -12460.712% |
MYUNGMOON Pharm co.,Ltd | 90.48 Billion KRW | 12.262% |
Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | -72.014% |
Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | -72.014% |
Korea United Pharm Inc. | 40.33 Billion KRW | -96.799% |
CKD Bio Corp. | 146.92 Billion KRW | 45.968% |
Daewoong pharmaceutical Co.,Ltd | 469.68 Billion KRW | 83.098% |
JW Holdings Corporation | 554.58 Billion KRW | 85.685% |
REYON Pharmaceutical Co., Ltd. | 225.05 Billion KRW | 64.725% |
Hanmi Pharm. Co., Ltd. | 572.86 Billion KRW | 86.142% |
Dong-A ST Co., Ltd. | 406.7 Billion KRW | 80.48% |
Chong Kun Dang Pharmaceutical Corp. | 219.76 Billion KRW | 63.876% |
JW Lifescience Corporation | 46.31 Billion KRW | -71.415% |
Ildong Pharmaceutical Co., Ltd. | 217.84 Billion KRW | 63.557% |
Jeil Pharmaceutical Co.,Ltd | 84.96 Billion KRW | 6.566% |
Hana Pharm Co., Ltd. | 26.53 Billion KRW | -199.2% |